Product image of Kengrexal (Cangrelor Tetrasodium) supplied by GNH India

Kengrexal

Active Ingredient:
Cangrelor Tetrasodium
Origin:
EU

Kengrexal (Cangrelor Tetrasodium)

Cangrelor Tetrasodium, the active ingredient in Kengrexal, is a P2Y12 receptor antagonist presented as a solution for injection for intravenous use. It is employed to prevent thrombotic complications during percutaneous coronary intervention and to provide antiplatelet therapy in patients with acute coronary syndromes undergoing invasive procedures.\n\nGNH India supplies Kengrexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for this injectable product globally.

Manufacturer / TM Owner

Chiesi Farmaceutici S.P.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Kengrexal, a P2Y12 receptor antagonist, is used in cardiovascular interventions to inhibit platelet aggregation.\n\n- Percutaneous coronary intervention (PCI): reduces risk of procedural thrombotic events.\n- Acute coronary syndrome undergoing invasive procedures: provides rapid antiplatelet effect during treatment.\n- Cardiac catheterization procedures: offers immediate platelet inhibition to support anticoagulation strategy.

How It Works

  • Cangrelor Tetrasodium binds reversibly to the platelet P2Y12 ADP receptor, blocking ADP‑mediated activation of the G_i protein pathway. This inhibition prevents the conformational change of the GPIIb/IIIa receptor, thereby reducing fibrinogen binding and platelet aggregation. The rapid onset and short half‑life allow precise control of antiplatelet activity during short‑duration procedures. It does not require metabolic activation and its effect diminishes quickly after infusion stops, facilitating timely restoration of normal platelet function.

Side Effects

  • Cangrelor Tetrasodium may be associated with several adverse reactions, ranging from common to serious.\n\nCommon Side Effects:\n- Bleeding at the injection site: mild to moderate\n- Mild hypotension: transient drop in blood pressure\n- Nausea: occasional gastrointestinal upset\n- Headache: mild to moderate intensity\n\nSerious or Rare Side Effects:\n- Severe or uncontrolled bleeding: may require medical intervention\n- Allergic reactions including anaphylaxis: rare but potentially life‑threatening\n- Thrombocytopenia: significant drop in platelet count\n- Myocardial infarction: rare cardiac event

Precautions & Warnings

  • When using Kengrexal, several precautions should be observed to minimize risks.\n- Renal impairment: monitor renal function and adjust therapy as needed.\n- Hepatic impairment: use with caution and observe for increased bleeding.\n- Concurrent anticoagulants: increased bleeding risk, consider dose adjustment.\n- History of bleeding disorders: avoid use or ensure close monitoring.\n- Upcoming surgery or invasive procedures: discontinue prior to the procedure as recommended.\n- Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

  • Cangrelor Tetrasodium can interact with other medications, affecting bleeding risk or drug efficacy.\n\nMajor Interactions (Avoid):\n- Co‑administration with other P2Y12 inhibitors: additive antiplatelet effect may cause severe bleeding.\n- Use with glycoprotein IIb/IIIa inhibitors: markedly increased bleeding risk.\n- Strong CYP3A4 inducers (if applicable): may reduce antiplatelet effect.\n\nModerate Interactions (Monitor Closely):\n- Heparin or low‑molecular‑weight heparin: additive anticoagulant effect, monitor coagulation parameters.\n- Warfarin or direct oral anticoagulants: heightened bleeding tendency, adjust monitoring.\n- Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased gastrointestinal bleeding risk.

Frequently Asked Questions

Kengrexal is indicated for the prevention of thrombotic complications during percutaneous coronary intervention (PCI) and for providing rapid antiplatelet therapy in patients with acute coronary syndromes who are undergoing invasive procedures such as angiography or stent placement.

Cangrelor Tetrasodium acts as a reversible inhibitor of the platelet P2Y12 ADP receptor. By blocking this receptor, it prevents ADP‑mediated platelet activation and aggregation, delivering fast and controllable antiplatelet effects during short‑duration cardiovascular procedures.

The dose of Kengrexal is determined by the prescribing clinician based on the specific clinical scenario, patient weight, renal and hepatic function, and the intended procedural context. Dosing recommendations are provided in the product’s prescribing information and should not be altered without medical guidance.

The safety of Cangrelor Tetrasodium in pregnancy or while breastfeeding has not been established. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Kengrexal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling) and required import documentation.

Unlike oral P2Y12 inhibitors such as clopidogrel or ticagrelor, Kengrexal is administered intravenously and provides immediate, reversible platelet inhibition with a short half‑life. This makes it especially useful for short procedures where rapid onset and quick offset of antiplatelet effect are desired.

Kengrexal should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the solution in its original packaging until use to maintain stability and sterility.

Kengrexal is supplied as a sterile solution for injection and is administered intravenously by a healthcare professional. The infusion rate and duration are set by the prescriber according to the clinical protocol for the specific procedure.

The most serious risks include severe or uncontrolled bleeding, allergic reactions such as anaphylaxis, and rare events like thrombocytopenia or myocardial infarction. Prompt recognition and management of these events are essential during and after administration.

Kengrexal should be avoided in patients with active major bleeding, known hypersensitivity to cangrelor or any component of the formulation, and in those for whom the risk of bleeding outweighs the clinical benefit, such as certain severe hepatic or renal impairment cases,

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cangrelor Tetrasodium

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT